Atnaujinkite slapukų nuostatas

El. knyga: Nano-Oncologicals: New Targeting and Delivery Approaches

Kitos knygos pagal šią temą:
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

This authoritative volume focuses on emerging technologies in cancer nano medicine, characterized by their multi-functionality and potential to address simultaneously diverse issues of clinical relevance in the treatment of cancer. The book consists of sixteen chapters divided into six sections: 1) Biological Barriers in Cancer; 2) Tumor Targeting; 3) Targeting the Immune System; 4) Gene Therapy; 5) Nano theranostics and 6) Translational Aspects of Nano-Oncologicals. The volume starts with an introduction describing the biological barriers associated with cancer therapy and highlighting ways to overcome such barriers through the use of nanotechnology. This is followed by an analysis of the two major targeting strategies currently under investigation in cancer therapy: namely, the targeting of cancer cells and the targeting of the immune system. In the first case, the book presents liposomal and polymer-based therapies, including photodynamic approaches. In the second case, it analyzes in detail the possibility of either improving the efficiency of the immune system toward preventing cancer progression (cancer immunomodulation) or generating responses against specific cancer antigens (cancer vaccines).

Beyond these targeting options, Nano-Oncologicals: New Targeting and Delivery Approaches presents the most recent technological advances in the area of nucleic acid-based therapies, along with those in the area of theranostics, where the design of multifunctional nano carriers becomes vital. Following the study of the most promising nanotechnologies around the development of nano-oncologicals, the book ends with an overview of regulatory and toxicological issues, which are critical in their translational pathway, and the presentation of a nucleic acid-based therapy case-study. This book is an important resource for scientists interested in the design and development of anticancer nanotechnologies and also to those aiming to push their technology through clinical development.

Part I Biological Barriers in Cancer
1 Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors
3(44)
Jaydev R. Upponi
Vladimir P. Torchilin
2 The "EX" and the "SOMA": How They Communicate
47(20)
Pinar Kanlikilicer
Mohammed Helmy Rashed
Bulent Ozpolat
Cristian Rodriguez-Aguayo
Anil K. Sood
George A. Calin
Gabriel Lopez-Berestein
Part II Tumor Targeting
3 Polymeric Nanocarriers for Cancer Therapy
67(28)
Peng Mi
Nobuhiro Nishiyama
4 Targeted Liposomes and Micelles as Carriers for Cancer Therapy
95(28)
Weiyue Lu
Changyou Zhan
Huimin Hou
5 Photodynamic Therapy for Cancer: Principles, Clinical Applications, and Nanotechnological Approaches
123(40)
Claudia Conte
Francesca Ungaro
Antonino Mazzaglia
Fabiana Quaglia
Part III Targeting the Immune System
6 Cancer Vaccines: Fundamentals and Strategies
163(24)
Javier Briones
7 Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches
187(28)
Maria Stella Sasso
Vincenzo Bronte
Ilaria Marigo
8 Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation
215(30)
Maria de la Fuente
Robert Langer
Maria Jose Alonso
Part IV Gene Therapy
9 RNAi-Based Nano-Oncologicals: Delivery and Clinical Applications
245(24)
Katharina Muller
Ernst Wagner
10 Nano-Platforms for Tumor-Targeted Delivery of Nucleic Acid Therapies
269(26)
Arun K. Iyer
Shanthi Ganesh
Mansoor M. Amiji
Part V Nanotheranostics
11 Multifunctional Gold Nanocarriers for Cancer Theranostics: From Bench to Bedside and Back Again?
295(34)
Joao Conde
Furong Tian
Pedro V. Baptista
Jesus M. de la Fuente
12 Microbubbles as Theranostics Agents
329(22)
Tuan Pham
Carl Beigie
Yoonjee Park
Joyce Y. Wong
13 Multimodal Nano-Systems for Cancer Diagnosis, Imaging and Therapy
351(40)
Amit Singh
Adwait J. Oka
Purva Pandya
Mansoor M. Amiji
Part VI Translational Aspects of Nano-Oncologicals
14 Nanotoxicology: Towards Safety by Design
391(34)
Fernando Torres Andon
Bengt Fadeel
15 Regulatory Aspects of Oncologicals: Nanosystems Main Challenges
425(28)
Rogerio S. Gaspar
Helena F. Florindo
Liana C. Silva
Mafalda A. Videira
M. Luisa Corvo
Barbara F. Martins
Beatriz Silva-Lima
16 BO-110, a dsRNA-Based Anticancer Agent
453(18)
Mercedes Pozuelo-Rubio
Damia Tormo Canilla
Andres P. Gagete
Maria Soengas
Index 471
Marķa José Alonso is Professor of Biopharmaceutics and Pharmaceutical Technology at the University of Santiago de Compostela (USC) in Spain. She has made critical contributions to the design of novel nanostructures for the targeted delivery of drugs and vaccines and to the understanding of the interaction of nanoparticles with biological barriers. She is part of the scientific boards of a number of societies and the executive board of the Controlled Release Society. She is also a member of the editorial board of eight prestigious journals in the field of drug delivery.

Marcos Garcia-Fuentes is an Associate Professor of Pharmacy at Spains University of Santiago de Compostela (USC), where he also obtained his Ph.D. He was a visiting scholar at Purdue University in Indiana, USA and a Marie Curie postdoctoral scientist at ETH Zurich in Switzerland. He was recognized with a competitive contract from the regional government for the reintegration of excellent researchers. Marcos has work in the design of biomaterials and nanostructures for medical applications. His current focus is on nanomedicines and biomaterials for modulating progenitor cells and cancer stem cells.